Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
XLO
HOLDXilio Therapeutics, Inc. · Healthcare · United States · $57M · Avg Vol: $457K/d
38
StockRankGet insider-trade alerts
Q
35
V
39
M
57
P/E (TTM)
—
ROE
-75.2%
D/E
0.1x
Dividend %
—
Loading 1Y...
PRICE (1Y)+9.4%
SMA 50SMA 200
Close
$9.09
RSI (14)
45.6
52W High
$12.74
From 52W High
0.7%
SCORE BREAKDOWN
Quality
35
ROIC
-42.9%17.9
ROE
-75.2%12.3
GP/Assets
27.4%62.0
Op. Margin
-111.6%16.9
FCF/Assets
-3.6%37.5
Piotroski
111.4
Int. Cover
—N/A
D/E Ratio
0.09x64.3
Current Ratio
3.59x60.5
Value
39
P/E (TTM)
—N/A
EV/EBITDA
2.3x25.0
P/FCF
—N/A
P/B
1.1x81.5
P/S
1.1x82.3
Div Yield
—N/A
Momentum
57
52W High %
71%56.4
RS 6M
-5%68.1
SMA 50/200
0.96x57.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+75%65.8
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$57M
P/E (Forward)
-14.9x
Gross Margin
79.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XLO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc.(you) | $57M | 38 | HOLD |
| BOLD | Boundless Bio, Inc. | $58M | 43 | HOLD |
| LONA | LeonaBio, Inc. | $69M | 30 | SELL |
| RLYB | Rallybio Corporation | $87M | 34 | SELL |
| NRXS | NeurAxis, Inc. | $84M | 33 | SELL |
| XBIT | XBiotech Inc. | $69M | 29 | SELL |
| ATRA | Atara Biotherapeutics, Inc. | $71M | 29 | SELL |
| VTVT | vTv Therapeutics Inc. | $121M | 39 | HOLD |
| PMVP | PMV Pharmaceuticals, Inc. | $66M | 25 | SELL |
| SEER | Seer, Inc. | $108M | 34 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%